Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the painful flare-ups associated with the disease. The discovery points to a potential new treatment for the autoimmune disorder and may also allow the use of a simple blood test to detect people at elevated risk for developing the condition.
The promising discovery is among the first to emerge from the School of Medicine’s new affiliation with Inova Health, a collaboration that aims to make medical breakthroughs and advance the battle against disease. In this case, the arthritis discovery originated in the lab of UVA’s Kodi Ravichandran, PhD, and was facilitated by combining his team’s resources and expertise with that of Inova researcher Thomas Conrads, PhD, through a THRIV UVA-Inova seed grant.
Understanding Rheumatoid Arthritis
The new findings about rheumatoid arthritis came in an unexpected fashion. Sanja Arandjelovic, PhD, a research scientist in the Ravichandran group, was seeking to better understand what causes the inflammation associated with inflammatory arthritis when she noted that deleting a gene called ELMO1 alleviated arthritis symptoms in mice. This was particularly surprising because Arandjelovic and Ravichandran initially thought that loss of ELMO1 would result in increased inflammation.
“This was a complete surprise to us initially,” recalled Ravichandran, chairman of UVA’s Department of Microbiology, Immunology and Cancer Biology. “I love those kinds of results, because they tell us that, first, we did not fully comprehend the scientific problem when we began exploring it, and, second, such unexpected results challenge us to think in a different way. Given that rheumatoid arthritis affects millions of people worldwide, we felt the need to understand this observation better.”
Digging deeper into the unusual outcome, the researchers determined that ELMO1 promotes inflammation via their function in white blood cells called neutrophils. Ravichandran described neutrophils as the body’s “first line of defense” because they sense and respond to potential threats. “Normally they are good for us, against many bacterial infections,” he said. “But also there are many times when they produce a lot of friendly fire that is quite damaging to the tissues – when they hang around too long or there are too many neutrophils coming in – in this case, infiltrating into the joints during arthritis.”
The researchers also discovered that there is a natural variation in the ELMO1 gene that can prompt neutrophils to become more mobile and have the potential to invade the joints in greater numbers and induce inflammation. (The potential blood test would detect this variation.)
Here things take a particularly cool turn: Normally, doctors are reluctant to try to block the effect of genes like ELMO1 in people, because such genes can play diverse roles in the body. But Ravichandran believes that ELMO1 is different. “ELMO1 partners with very specific set of proteins only in the neutrophils but not in other cells types we tested,” he said. “So, presumably, you may be able to affect only a select cell type.” This latter result came about from a collaborative study where Conrads’ group at Inova performed sophisticated analysis of ELMO1 proteomic partners in neutrophils, many of which also have previously known links to human arthritis. This provided further validation for the role of ELMO1 in rheumatoid arthritis.
Encouragingly, blocking ELMO1 in lab mice alleviated arthritis inflammation without causing other problems, Ravichandran noted. His laboratory is now seeking to identify drugs that could inhibit the function of ELMO1 and is also designing a test for the variation (also called polymorphism) in the ELMO1 gene.
“This is another example of how fundamental basic research can lead to novel discoveries on clinically relevant problems that affect a large number of people,” Ravichandran said.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Pfizer Sues Over Generic For Arthritis Drug Xeljanzon January 12, 2021 at 3:28 pm
Pharmaceutical giant Pfizer has asked a Delaware federal court to block generic-drug maker Aurobindo Pharma from moving ahead with plans to sell a generic version of arthritis drug Xeljanz that Pfizer ...
- Dr. Keith Roach: Arthritis treatment needed for pain in handson January 11, 2021 at 10:13 pm
Dear Dr. Roach • I would like to know how to treat arthritis. I have been using Voltaren per my doctor’s orders, but it does not seem to be helping ...
- Pfizer/BioNTech vaccine works against virus variants in lab; arthritis drugs improve COVID-19 survivalon January 8, 2021 at 5:55 pm
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
- Arthritis drugs may reduce mortality and time in ICU for sickest COVID patientson January 8, 2021 at 7:12 am
Treating critically ill COVID-19 patients with drugs typically used for arthritis may significantly improve survival, a landmark study has found.
- Rheumatoid Arthritis Market: Emerging Technologies, Competition & Strategies of Key Players, Regional Analysis and Forecast By 2022on January 8, 2021 at 6:20 am
The global Rheumatoid Arthritis Market is profiled in detail in the latest research report from Market Research ...
- Believe Project: $100 to help woman with rheumatoid arthritison January 7, 2021 at 9:00 pm
Today's recipient of a $100 bill through the Believe Project is Eileen LePoire of Bolingbrook. LePoire wants to give the money to a woman with rheumatoid arthritis. Here is an excerpt of her story: ...
- Rheumatoid arthritis drugs work against severe coronavirus cases: studyon January 7, 2021 at 11:13 am
The drugs, tocilizumab and sarilumab, were successful in treatment severe coronavirus cases. Scientists conducting a study looking at two drugs typically used to treat rheumatoid arthritis — ...
- The Best Apps for Rheumatoid Arthritison January 6, 2021 at 9:16 am
Managing the effects of rheumatoid arthritis can be tricky. But apps for your smartphone or tablet can help you and your doctor find the best way to manage your RA.
- Rheumatoid Arthritis Mythson January 6, 2021 at 9:16 am
Thanks to an abundance of easy-to-find (but not always accurate) information, many people have misconceptions about rheumatoid arthritis (RA). Two rheumatologists explain the truth behind some of the ...
- Rheumatoid Arthritis Therapeutics Market Insights, Production, Demand and from 2020 to 2026on January 5, 2021 at 2:13 pm
The Rheumatoid Arthritis Therapeutics (RA) market is expected to grow from $23.3bn in 2017 to $27.8bn in 2027 across the eight major markets (US, France, Germany, Italy, Spain, the UK, Japan, and ...
via Bing News